Azitra (AZTR) Cash from Investing Activities (2022 - 2026)
Azitra (AZTR) posted Cash from Investing Activities of -$37139.0 for Q1 2026, up 55.71% on a QoQ basis from -$83858.0 in Q4 2025, and down 71.26% year-over-year from -$129214.9 in Q1 2025.
Azitra (AZTR) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Azitra's Cash from Investing Activities history runs 5 years deep, the most recent figure standing at -$37139.0 for Q1 2026.
- Quarterly Cash from Investing Activities fell 71.26% year-over-year to -$37139.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198362.0 (up 37.98% YoY) and the FY2025 annual result came in at -$182909.0, up 51.77% from the prior year.
- Cash from Investing Activities was -$37139.0 for Q1 2026 at Azitra, up from -$83858.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$21686.0 in Q1 2025 and bottomed at -$115532.0 in Q4 2024.
- A 5-year average of -$70098.7 and a median of -$79304.0 in 2023 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 158.87% — and 2025, when it surged 73.25%.
- Azitra's Cash from Investing Activities stood at -$96791.0 in 2022, then surged by 38.03% to -$59985.0 in 2023, then sank by 92.6% to -$115532.0 in 2024, then gained by 27.42% to -$83858.0 in 2025, then surged by 55.71% to -$37139.0 in 2026.
- Business Quant data shows AZTR's Cash from Investing Activities at -$37139.0 in Q1 2026, -$83858.0 in Q4 2025, and -$41078.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.11 Bn | 1,785.05 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.57 Bn | 468.78 Bn | 1.35 Bn | -45.51 Mn |
| 4 | Vertex Pharmaceuticals | 123.78 Bn | 116.54 Bn | 2.59 Bn | -431.90 Mn |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.98 Bn | 3.31 Bn | -428.90 Mn |
| 6 | Belite Bio | 62.12 Bn | 62.12 Bn | - | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.05 Bn | 35.05 Bn | 959.66 Mn | -25.54 Mn |
| 9 | Revolution Medicines | 36.28 Bn | 36.28 Bn | - | 172.62 Mn |
| 10 | Azitra | 2.03 Mn | 2.03 Mn | - | -37,139.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37,139.00 |
| Mar 31, 2026 | -37,139.00 |
| Dec 31, 2025 | -83,858.00 |
| Dec 31, 2025 | -83,858.00 |
| Sep 30, 2025 | -41,078.00 |
| Sep 30, 2025 | -41,078.00 |
| Jun 30, 2025 | -36,287.00 |
| Jun 30, 2025 | -36,287.00 |
| Mar 31, 2025 | -21,686.00 |
| Mar 31, 2025 | -21,686.00 |
| Dec 31, 2024 | -115,532.00 |
| Dec 31, 2024 | -115,532.00 |
| Sep 30, 2024 | -107,888.00 |
| Sep 30, 2024 | -107,888.00 |
| Jun 30, 2024 | -74,748.00 |
| Jun 30, 2024 | -74,748.00 |
| Mar 31, 2024 | -81,078.00 |
| Mar 31, 2024 | -81,078.00 |
| Dec 31, 2023 | -59,985.00 |
| Dec 31, 2023 | -59,985.00 |